TB-500 + MOTS-c Stack: Complete Protocol, Dosing, and Evidence Review

What Is TB-500 and How Does It Work?

TB-500 refers to the commercially sold synthetic fragment of thymosin beta-4, specifically the tetrapeptide Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline). Full-length thymosin beta-4 is a 43-amino-acid protein encoded by the TMSB4X gene on the X chromosome. The Ac-SDKP fragment retains a significant portion of the parent molecule's activity related to actin regulation and tissue repair.

Mechanism: Actin Sequestration and Cell Migration

Thymosin beta-4 sequesters G-actin (monomeric actin), which controls the polymerization state of the actin cytoskeleton. This regulates cell migration, an essential step in wound repair. A 2010 study published in the Annals of the New York Academy of Sciences confirmed that Tβ4's actin-binding domain drives re-epithelialization and angiogenesis in corneal and dermal wound models 1.

Mechanism: Anti-Inflammatory Signaling

TB-500 also suppresses NF-κB signaling. In a murine myocardial infarction model, thymosin beta-4 reduced inflammatory cytokine expression and decreased infarct size by approximately 20% compared with controls 2. The anti-inflammatory effect is at least partly independent of the actin-binding function, suggesting the peptide works through multiple pathways simultaneously.

Regulatory and Safety Context

The FDA has not approved any thymosin beta-4 product for human use. The Ac-SDKP fragment has been detected in human plasma at picomolar concentrations and is produced endogenously by mast cells. That endogenous presence does not constitute safety approval. The FDA's 503A/503B compounding framework governs how such peptides may be prepared by licensed pharmacies, and neither TB-500 nor full-length Tβ4 appears on the FDA's current list of bulk substances permitted for compounding 3.

What Is MOTS-c and How Does It Work?

MOTS-c is a 16-amino-acid peptide whose sequence is encoded within the mitochondrial 12S ribosomal RNA gene, making it one of a small family of mitochondrial-derived peptides (MDPs). Its discovery was reported in 2015 by Lee et al. In Cell Metabolism, where it was shown to regulate insulin sensitivity and energy homeostasis through AMPK activation 4.

Mechanism: AMPK and Metabolic Flexibility

MOTS-c translocates from mitochondria to the nucleus under conditions of metabolic stress. Inside the nucleus it regulates antioxidant response element (ARE) genes, increasing cellular resistance to oxidative stress. Its activation of AMP-activated protein kinase (AMPK) mimics the metabolic effects of caloric restriction and exercise, increasing fatty acid oxidation and reducing hepatic glucose output.

In the original Lee et al. Study (N=mice, high-fat diet model), MOTS-c treatment produced a statistically significant reduction in body weight and improved insulin tolerance compared with vehicle controls (P<0.05) 4. The effect was blocked by an AMPK inhibitor, confirming pathway specificity.

Mechanism: Inflammation and Cellular Resilience

A 2021 paper in Nature Aging showed that circulating MOTS-c levels decline with age in humans and that MOTS-c supplementation extended healthspan in aged mice by reducing systemic inflammatory markers, including IL-6 and TNF-alpha 5. MOTS-c also appears to modulate FOXO1 transcription factor activity, which connects it to longevity-associated gene networks.

Serum MOTS-c was measurably higher in centenarians compared with healthy middle-aged controls in one Japanese cohort study (median 318 pg/mL vs. 187 pg/mL, P<0.01) 5. This is an association, not causation, and should be interpreted carefully.

Regulatory Status

MOTS-c has no FDA-approved indication. It is not listed among approved drugs on the FDA Orange Book 6. Practitioners who prescribe or recommend it do so outside any approved labeling, and patients should understand that the evidence base is primarily preclinical.

Why Stack TB-500 with MOTS-c? The Mechanistic Rationale

These two peptides address largely non-overlapping biological targets, which is the core reason they appear frequently together in practitioner protocols. The combination targets local tissue repair (TB-500) alongside systemic metabolic and mitochondrial optimization (MOTS-c).

Complementary Rather Than Redundant Pathways

TB-500 operates primarily at the extracellular matrix and cytoskeletal level, promoting cell migration, angiogenesis, and collagen deposition. MOTS-c operates at the organelle-to-nucleus axis, improving the energy substrate that repair cells need. Think of it this way: TB-500 sends the construction crew; MOTS-c fuels the generators.

Both peptides show NF-κB suppression in their respective models, which may produce an additive anti-inflammatory effect. No study has directly measured this combination, so the additive assumption remains theoretical.

The Athlete and Aging Recovery Context

Soft-tissue injuries in athletes and age-related declines in repair capacity share a common deficit: inadequate local angiogenesis combined with mitochondrial dysfunction in satellite cells and fibroblasts. A 2020 review in Frontiers in Physiology noted that mitochondrial dysfunction directly impairs skeletal muscle regeneration by reducing the ATP available to activated satellite cells 7. MOTS-c's ability to restore mitochondrial metabolic capacity in aged cells makes it a logical adjunct to a tissue-repair peptide.

Evidence Quality Rating

| Domain | TB-500 Evidence | MOTS-c Evidence | Stack Evidence | |---|---|---|---| | Cell / in vitro | Strong | Strong | None | | Animal in vivo | Moderate | Moderate | None | | Human RCT | None | None | None | | Practitioner case series | Limited | Limited | Anecdotal |

No peer-reviewed study has examined TB-500 and MOTS-c in combination. Every protocol recommendation in this article, and in the field generally, is extrapolated from individual compound data.

Complete Dosing Protocol

The dosing ranges below are derived from animal study dose conversions using the FDA's body surface area (BSA) scaling formula, from the limited human pharmacokinetic data available for thymosin beta-4 metabolites, and from practitioner-reported protocols circulating in clinical peptide communities. They are not FDA-approved doses.

Loading Phase (Weeks 1-6)

TB-500

• Dose: 2.0-2.5 mg subcutaneous injection
• Frequency: twice weekly (e.g., Monday and Thursday)
• Injection site: rotate between abdomen, lateral thigh, or deltoid subcutaneous fat
• Reconstitution: 2 mg lyophilized peptide in 1-2 mL bacteriostatic water (yields 1-2 mg/mL)

MOTS-c

• Dose: 5-10 mg subcutaneous injection
• Frequency: three times weekly (e.g., Monday, Wednesday, Friday) or twice weekly for a lower-intensity start
• Injection site: subcutaneous abdomen preferred based on animal absorption data
• Reconstitution: 10 mg lyophilized in 2 mL bacteriostatic water (yields 5 mg/mL)

These two peptides may be injected on the same days but should use separate syringes and separate injection sites. No compatibility data exist for co-administration in a single syringe, and mixing is not recommended.

Maintenance Phase (Weeks 7-12)

TB-500

• Dose: 2.0 mg subcutaneous
• Frequency: once weekly
• Rationale: animal studies suggest repair signaling persists after the loading period; weekly dosing may sustain benefit without accumulation

MOTS-c

• Dose: 5 mg subcutaneous
• Frequency: twice weekly
• Rationale: AMPK activation from MOTS-c appears to have a duration-of-effect of roughly 48-72 hours in rodent models, supporting a twice-weekly schedule

Cycle Off and Re-Assessment

After 12 weeks total, a minimum 4-week off-cycle is a common practitioner recommendation. This is not supported by specific human pharmacokinetic data for either peptide. Re-assessment should include whatever biomarkers prompted the original protocol (e.g., inflammatory markers, DEXA body composition, injury imaging) rather than subjective feel alone.

The HealthRX Peptide Stack Decision Framework applied here uses four gates before recommending any stack: (1) confirmed mechanistic non-redundancy, (2) no known pharmacodynamic antagonism, (3) independent safety signals reviewed per compound, and (4) a defined biomarker re-check endpoint. TB-500 and MOTS-c pass gates 1 and 2 based on available data. Gate 3 flags the absence of long-term human safety data for both. Gate 4 requires a 12-week re-assessment appointment before extending or repeating the cycle.

Who May Benefit From This Stack?

Practitioners most commonly report using this combination in four populations, though none of these indications are FDA-approved.

Athletes With Recurrent Soft-Tissue Injuries

Tendon and ligament injuries represent the most cited application for TB-500. A 2010 study in Annals of the New York Academy of Sciences demonstrated accelerated tendon repair in a rat Achilles model with full-length Tβ4 1. Adding MOTS-c in this population is speculative, premised on the idea that improved mitochondrial function in tenocytes and satellite cells may accelerate healing timelines.

Adults Over 40 With Declining Recovery Capacity

MOTS-c's documented decline with age provides a mechanistic rationale for supplementation in older adults, though no RCT has confirmed that exogenous MOTS-c restores youthful recovery rates. The Nature Aging data showing lower MOTS-c in older vs. Younger adults is associational 5.

Metabolically Compromised Patients Undergoing Exercise Rehabilitation

In patients with insulin resistance or early type 2 diabetes, MOTS-c's AMPK-activating effects may provide metabolic benefit alongside any structural repair from TB-500. The 2015 Lee et al. Cell Metabolism paper showed an 18% reduction in fasting glucose in high-fat-diet mice treated with MOTS-c vs. Controls 4.

Who Should Not Use This Stack

Patients with active malignancy should avoid both peptides. Thymosin beta-4 has been shown to promote angiogenesis, which theoretically could support tumor vascularity 8. MOTS-c's effects on cell proliferation signaling are incompletely characterized. Pregnant women, patients on immunosuppressive therapy, and anyone with uncontrolled autoimmune disease should not use this combination without direct physician oversight and a well-documented risk-benefit discussion.

Safety Profile and Known Adverse Effects

Neither peptide has a human safety dataset from a completed Phase I or Phase II RCT. The following information comes from animal toxicology studies, case reports, and practitioner-aggregated patient experience.

TB-500 Adverse Effects

Reported adverse effects in practitioner settings include transient injection-site redness (the most common complaint), mild fatigue in the first 1-2 weeks, and occasional headache. One theoretical concern is the peptide's pro-angiogenic activity in the context of occult or pre-malignant lesions, as noted above. No cardiotoxicity signals have been reported in rodent models at standard doses.

MOTS-c Adverse Effects

Reported adverse effects include transient hypoglycemia-like symptoms (lightheadedness, mild sweating) in fasted patients, consistent with the peptide's glucose-lowering mechanism. Patients on metformin or GLP-1 receptor agonists should flag this risk with their prescribing physician, because additive glucose lowering is possible. No serious adverse events have been published in the preclinical literature at doses extrapolated to human equivalents.

Drug Interactions

No formal drug interaction studies exist for either peptide. Theoretical interactions include:

• Additive glucose lowering with metformin, SGLT2 inhibitors, or GLP-1 agonists (MOTS-c)
• Possible potentiation of angiogenic effects if used with vascular endothelial growth factor (VEGF) therapies (TB-500)
• Unknown interactions with immunomodulatory drugs given TB-500's immune-relevant mechanism

The FDA's pharmacovigilance database (FAERS) does not contain reportable adverse events specifically attributed to TB-500 or MOTS-c as of January 2025, though this reflects reporting gaps rather than confirmed safety 9.

Monitoring and Labs

A responsible protocol pairs peptide use with objective monitoring. The following panel is what the HealthRX medical team recommends before, at week 6, and at week 12 for patients on this stack.

Baseline Labs

• Complete metabolic panel (CMP) with fasting glucose and HbA1c
• Lipid panel
• CBC with differential
• Inflammatory markers: hsCRP and IL-6 if available
• IGF-1 (to rule out pre-existing growth factor dysregulation)
• Testosterone and SHBG if on concurrent TRT

Week 6 Interim Check

• Fasting glucose and insulin (HOMA-IR calculation)
• hsCRP
• Subjective injury or pain score using a validated scale (e.g., VISA-A for Achilles tendinopathy)
• Injection-site inspection

Week 12 Full Re-Assessment

• Repeat full baseline panel
• DEXA scan if body composition is a primary goal
• Imaging of target injury site if applicable
• Physician review before extending the cycle

Sourcing and Quality Considerations

Peptide purity is a serious concern. A 2018 analysis of research-grade peptides sold online found that 36 of 44 samples tested contained the labeled peptide at less than 90% purity, and 8 samples contained unlabeled compounds 10. Patients should only obtain peptides through a licensed 503A or 503B compounding pharmacy with a valid prescription, where USP <797> sterility standards apply and certificates of analysis are routinely provided.

Sourcing from research chemical websites bypasses any regulatory oversight and cannot be recommended. The FDA has issued multiple warning letters to companies marketing injectable peptides without appropriate licensing 3.